LLY stock verdict - Growth
LLY
Eli Lilly and Company
GROWTHHealthcare
$1,196.03
Watch (wait for dip)
$1,196.03
Heavy$863.75Buy$1,151.67Fair$1,439.59Exit$1,727.51
FUNDAMENTAL84
TECHNICAL85
TRUST SCORE
100High
confidence in this read — data completeness, earnings quality & coverage
Uptrend · EMA20 1171.97 · EMA50 1127.73 · EMA200 1012.02 · RSI 57.0 · MACD below signal
PROS
- Trades 17% below the model's fair value ($1,439.59)
- Strong return on equity of 87.6% (TTM)
- Revenue grew 32.1%/yr on average over the last 3 years
- High gross margin of 81% (3-yr avg)
- Price is in an uptrend — above key moving averages with positive momentum
CONS
- Expensive on trailing earnings (P/E 43.1×)
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
EARNINGS QUALITY · we check the accounting so you don't have to
✓Operating cash flow is 81% of net income — profit is backed by real cash
✓Low accruals — reported profit tracks the cash actually generated
✓Receivables growing in line with sales
SECTOR PEERS
Analysis as of 2026-07-27 · price live, fundamentals from latest filings
FAQ
Why is LLY rated Growth?
LLY (Eli Lilly and Company) is rated Growth because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Watch (wait for dip). Trades 17% below the model's fair value ($1,439.59) and Strong return on equity of 87.6% (TTM)
Is LLY overvalued right now?
LLY is trading at $1,196.03 versus an estimated fair value of $1,439.59. That puts the stock in growth territory on this framework. Expensive on trailing earnings (P/E 43.1×)
What should I watch before acting on LLY?
Watch the trust score of 100, the earnings-quality checks, and any red flags. Expensive on trailing earnings (P/E 43.1×)